Best Hopkins Biotech Podcast Podcasts (2024)

1
Roivant: Reinventing the Paradigm of Conventional Drug Development 51:27

8M ago51:27

51:27

Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strateg…

1
Public Relations and Scientific Communications for Biotechnology with Ignacio Guerrero-Ros 44:24

8M ago44:24

44:24

Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners, providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einst…

1
What You Should Know About the Biotech Job Market in 2023 with Carina Clingman 56:31

10M ago56:31

56:31

Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting, a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collabor…

1
Antibody-Drug Conjugates: Targeting Cancer Where it is Vulnerable with David Dornan of Elevation Oncology 28:53

11M ago28:53

28:53

About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multipl…

1
Boston Biotech Series: Standing out in the Competitive Recruiting Process for Early Stage Biotech 29:23

1y ago29:23

29:23

Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital. In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading an…

1
Boston Biotech Series: Building a Drug Development Platform on New Biology with Isaac Klein of Dewpoint Therapeutics 38:20

1y ago38:20

38:20

Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines t…

1
Jodi Akin and The Hawthorne Effect Inc. (Encore) 41:33

1y ago41:33

41:33

1
Lab Before Slab: Our Two Cents about Elizabeth Holmes and Theranos, Inc. (Encore) 18:13

1y ago18:13

18:13

1
Lab Before Slab: Technology and Mental Health (Encore) 12:45

1+ y ago12:45

12:45

1
Fostering Collisions for Medical Innovation: The Jacobs Institute (Encore) 30:18

1+ y ago30:18

30:18

1
Lab Before Slab: A New Device for Menstrual Health (Encore) 13:42

1+ y ago13:42

13:42

1
Stroke Adventurer, Dr. Nick Hopkins (Encore) 40:22

1+ y ago40:22

40:22

1
Boston Biotech Series: Facilitating Start-up Company Formation with Adam Jenkins of Biolabs 36:26

1+ y ago36:26

36:26

Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs. BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more th…

1
Lab Before Slab: In A World Without Fries... (Encore) 13:07

1+ y ago13:07

13:07

1
A GPS for Cancer: Sam Mazin Brings Hope to Late Stage Cancer Patients (Encore) 35:45

1+ y ago35:45

35:45

1
Lab Before Slab: Can You Hear Me Now Telehealth? (Encore) 14:29

1+ y ago14:29

14:29

1
JPM Highlights: What’s Next in ImmunoOncology 59:00

1+ y ago59:00

59:00

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s missio…

1
Meet Hector DeLuca, The Godfather of Vitamin D Research (Encore Edition) 38:44

1+ y ago38:44

38:44

1
Lab Before Slab: Off Label Prescriptions — Loophole or Hypocrisy (Encore Edition) 12:44

1+ y ago12:44

12:44

1
Scratching An Itch with Evan Anderson (Encore Edition) 34:05

1+ y ago34:05

34:05

1
Lineage Cell Therapeutics: Building an Allogeneic Cell Transplant Therapy Platform 28:41

1+ y ago28:41

28:41

Brian Culley is the CEO of Lineage Cell Therapeutics, a clinical-stage biotech company whose mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage currently has several programs undergoing clinical and preclinical investigation for indications in ophthalmology,…

1
Lab Before Slab: USA is #1 (in testing med tech devices) Encore! 13:55

1+ y ago13:55

13:55

1
JPM Highlights: Overcoming Complications in Rare Disease Drug Development 46:34

1+ y ago46:34

46:34

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals, a clinical-stage c…

1
The Amazing GammaTile for Recurrent Brain Tumors (Encore Edition) 38:20

1+ y ago38:20

38:20

1
Lab Before Slab: Health Equity in Clinical Trials (Encore Edition) 12:23

1+ y ago12:23

12:23

1
Electricity as Medicine: Cala Health (Encore Edition) 51:31

1+ y ago51:31

51:31

1
A Little About Lab Before Slab! (Encore Edition) 2:05

1+ y ago2:05

2:05

Lab Before Slab is the mini-pod companion to the Before We Die Podcast. These are the conversations that happen around our virtual production table when we should be doing other things. But often, these seemingly random conversations lead to interesting thoughts and topics and we wished that we recorded them. One day we did and thus, the Lab Before…

1
Lab Before Slab: A Pill to Replace Exercise? Yes, Please! (Encore Edition) 14:07

1+ y ago14:07

14:07

Scientists at Baylor and Stanford are researching a simple protein that may be able to reduce your caloric intake. John objects and blames the patients. The other hosts are the patients and object to John. Sandy plays the electric bike card. Craig accuses John of having a romantic notion of neurochemistry, which leads, of course, to bears. SHOW NOT…

1
Adrian Rubstein: translating science to business in the Latin American biotech ecosystem 53:45

1+ y ago53:45

53:45

Adrian is an advisor for several biotech companies in Argentina. Before joining CITES, a venture builder from Argentina, he worked as an advisor for RedCrow VC in San Francisco, and has more than 10 years working in the pharmaceutical industry in companies like Novartis and Merck KGaA. In this episode, we discuss his path from academia to big pharm…

1
Can Innovation Be Taught? Paul Yock and the Stanford Biodesign Program (Encore Edition) 41:07

1+ y ago41:07

41:07

As a professor at the Stanford School of Medicine, Dr. Paul Yock wanted to find a way pay it forward. Stanford BioDesign is the result of that vision. Along with our very own Sandra Miller, they created a program that brought together problem solvers from different fields and taught them how to form cross-discipline teams identifying and solving pa…

1
A little about Before We Die! 2:00

1+ y ago2:00

2:00

Your health is at stake. Are there medical innovations that could save your life? Or even just make your day to day living a little more comfortable? Join us for Before We Die, a roundtable conversation podcast that will open the door to the world of medical technology and introduce you to the innovators who tackle health problems in search of a be…

1
Let's Start with the Heart with Dr. Paul Yock! Encore Edition 43:23

1+ y ago43:23

43:23

Meet Dr. Paul Yock! Dr. Yock is famous for fundamentally improving cardiac interventions over his entire career. He walks us through the basics of a heart attack and how they were treated from the time his career began to now. His Rapid Exchange (RX) catheter innovation "rapidly" became the global standard. As the treatment for heart attack evolved…

1
Cyclacel Pharmaceuticals: Interventions for Cell Cycle Abnormalities in Cancer 38:56

1+ y ago38:56

38:56

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalat…

1
Reintroducing the Before We Die Creators 8:19

1+ y ago8:19

8:19

There are exciting advances happening in the med-tech world and patients are the last to know. Sandra Miller, John MacMahon and Craig Ullman join forces to share their humor and expertise about the med tech world in this patient-centered podcast. Innovation is happening and the devices that are emerging have the ability to save or significantly cha…

1
Melatech: Unlocking Melanin’s Biotech Potential for the Benefit of Society in Earth and Space 47:11

1+ y ago47:11

47:11

Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at indu…

1
Ratio Therapeutics: Math Meets Medicine in the Design of Radiotherapies 43:27

2y ago43:27

43:27

Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of …

1
Anupam Chakravarty: Building Community in the Graduate Education Landscape 40:24

2y ago40:24

40:24

Dr. Anupam Chakravarty is a researcher whose research interests have straddled the disciplines of biochemistry and genomics with a keen focus on the biology of cancer. Currently, he is a senior scientist developing liquid biopsy assays and products in the precision oncology space at Guardant Health. Prior to joining Guardant Health, he ran his own …

1
Tony Russo: A Multi-Decade View of the Biotechnology Industry 54:42

2y ago54:42

54:42

Dr. Tony Russo Ph.D. is the Chairman, CEO, and founder of Russo Partners, a leading public and investor relations firm. He has been a member of the healthcare and technology PR and IR community for more than three decades. As a founder of Noonan/Russo in 1988, he and his colleagues have helped build signature healthcare brands worldwide. A frequent…

1
Robert Hollingsworth: The Future of iPSC-based Cell Therapy Technology 45:34

2y ago45:34

45:34

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer an…

1
Shelley Ackerman: Immunotherapeutics Development in Graduate School 32:07

2y ago32:07

32:07

Dr. Shelley Ackerman is an Associate Director & Program Team Lead at Bolt Biotherapeutics. Bolt is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Biotherapeutics’ proprietary Boltbody™ Immun…

1
James Coates: Company Growth Through Strategic Advising 24:21

2y ago24:21

24:21

Dr. James Coates is currently the Principal for Health & Human Performance at Decisive Point, an East coast venture capital firm that invests in and supports startups with deep tech and government use cases. James holds a Ph.D. in Cancer Drug Discovery and MSc in Radiation Biology and Oncology, both from the University of Oxford, and he conducted t…

1
Philip Kantoff: Next Generation Radiopharmaceutical Drug Development 37:51

2y ago37:51

37:51

Dr. Phil Kantoff is the CEO and Co-Founder of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncolo…

1
Steve Doberstein: Scaling Technologies from Idea to Clinical Development 57:47

2y ago57:47

57:47

Dr. Steve Doberstein has had a long career leading Research groups at a number of biotech companies, like “XOMA”- a monoclonal antibody discovery and development company, “Five Prime Therapeutics”- a protein and antibody discovery and development company, “Xencor”- a leader in protein engineering and “Exelixis”-a genomics-based drug discovery compa…

1
Daniel Elgort: Data Driven Insights into the Drug Development Pipeline 48:22

2y ago48:22

48:22

Dr. Daniel Elgort currently serves as the Chief Data and Analytics Officer for M2GEN, a bioinformatics company focused on the acceleration of oncology research discoveries through superior data and analytics services. The company was formed as a spin-off of the Moffitt Cancer Center in Tampa, Florida, serving as the technological hub for an allianc…

1
Hong Tang: Targeting the Common Side Effects of Cancer Therapies 26:14

2y ago26:14

26:14

Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies- to improve the quality of life and outcomes for patients fighting cancer. Prior to founding OnQuality, sh…

1
Apprentice.io: The Future of Digitization in Pharmaceutical Production 32:10

2y ago32:10

32:10

Laura Jacoby is currently an Application Specialist at Apprentice.io, an innovative tech company that offers cloud-based solutions that impact pharmaceutical production at every stage of development. Their goal is to introduce digitization of records in an industry that until recently has operated mainly in a paper and pen world. Laura has a career…

1
Alex Harding M.D.: Business Development of Innovative Therapeutic Modalities 41:54

2+ y ago41:54

41:54

Alex Harding is a Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics, a Boston-based biotech company developing small molecules that alter RNA processing prior to protein translation. Their REMaster platform “enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon…

1
All about the Maryland Blue Crab! Presenting a Collaboration with The Sci'more Podcast 26:16

2+ y ago26:16

26:16

The crab season is here! If you are a Baltimore resident, you might have enjoyed dozens of our famous blue crabs, perhaps dozens of dozens every year. If you are new to Baltimore, you must have been encouraged to try them. Blue crabs are indeed tasty, but other than their nice savor, what do we know about them? This week on Sci'more podcast, crab b…

1
Rachel Soloff and Andrew McKnight: Pioneering Monoclonal Antibody Discovery and Development 46:01

2+ y ago46:01

46:01

Our episode features two leaders at the global specialty pharmaceutical company Kyowa Kirin. Kyowa Kirin has a particular focus on the discovery and development of novel, first-in-class medicines that have a profound impact on patients in multiple therapeutic areas. Rachel Soloff is an executive director of research with expertise in immunology and…

1
My PhD - McKane Sharff: Research at School of Public Health 25:27

2+ y ago25:27

25:27

McKane is a 5th year PhD student in the Department of Population, Family and Reproductive Health at Johns Hopkins Bloomberg School of Public Health She is conducting her PhD project under supervision of Dr. Terri Powell (https://www.researchbypowell.com/) trying to identify how multiple levels of support interact to influence positive sexual health…

Podcasts Worth a Listen

Hopkins Biotech Podcast

Podcasts Worth a Listen

Quick Reference Guide